Navigation Links
First aid after tick bites
Date:12/19/2011

This press release is available in German.

For years, Mrs. S. suffered from joint pain and headaches. After an odyssey through doctors' waiting rooms, one doctor diagnosed Lyme borreliosis an infectious disease transmitted by ticks. With its bite, the parasite introduced bacteria that then spread throughout the entire body. Mrs. S. is not alone very often, the disease is recognized too late or not at all, or is not properly treated. Doctors are provided with no clues if the characteristic redness around the bite area is missing. Left untreated, Lyme borreliosis can cause symptoms that resemble rheumatism, damage joints, muscles and nerves and affect the organs.

If found in time, it can be successfully treated. If patients exhibit the disease-specific rash known as erythema migrans, doctors will prescribe antibiotics for several weeks. However, if, as in the case of Mrs. S., the disease has progressed far and is chronic, it is very difficult to treat. Currently, there is no prophylactic treatment and no vaccine against the infection. In the future, a new type of gel is supposed to nip the infection in the bud: the patient applies it locally immediately after the tick's bite. Researchers of the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig developed the medication in close cooperation with the Swiss company Ixodes AG and the Institute for Infectious Diseases and Zoonoses of the Ludwig-Maximilian University in Munich (Institut fr Infektionsmedizin und Zoonosen der LMU Mnchen). Ixodes AG is responsible for developing the formula, while IZI and LMU are carrying out the pre-clinical studies and the serological examinations.

If the gel is applied immediately to the bite after the tick has been removed and one does not wait for any potential symptoms to show, Lyme borreliosis could be prevented. This is because during the first few days, the bacteria stay right around the spot where the tick bite occurred and spread out only after that. The active ingredient of the gel is azithromycin, which is highly effective against borrelia bacteria and kills them locally in the skin," says Dr. Jens Knauer, project manager at IZI. Unlike other antibiotics, there is no known resistance of borrelia strains against azithromycin. Another advantage of the active ingredient: it has few side effects and as a result does not stress the body. It also distinguishes itself by its good depot action of up to five days in the tissue. The treatment is successful only if the medication is applied within the first few days after the tick's bite. This gel, however, cannot be used to treat an established infection; it is suitable only for prophylaxis," emphasizes Dr. Knauer.

The pre-clinical studies have already been completed successfully; in mice, the gel was effective even five days after a tick's bite. The application has been patented. Starting this past summer, in a clinical phase III study (http://www.zeckenstudie.com), the researchers are testing the medication on persons with proven tick bites. Should the results of the pre-clinical studies be confirmed on humans, the gel will help to significantly lower the number of new infections," the expert adds. Annually, up to 60,000 are stricken with Lyme borreliosis in Germany alone, according to estimates by the Robert Koch Institute, with an upward trend since, due to climate change, ticks are expanding their range ever further. As soon as the gel can be purchased at the pharmacy, persons who are particularly endangered, such as forest rangers, hunters, joggers or soccer players, should always carry it with them," Knauer recommends.


'/>"/>
Contact: Dr. Jens Knauer
jens.knauer@izi.fraunhofer.de
49-341-355-361-206
Fraunhofer-Gesellschaft
Source:Eurekalert

Related biology news :

1. Chinese scientists announce the first complete sequencing of Mongolian genome
2. Worlds first super predator had remarkable vision
3. Max Planck Florida Institute scientists create first realistic 3D reconstruction of a brain circuit
4. Singapore and China scientists perform first Asian genome-wide association study on spine disease
5. Microscopic cells race to victory in first World Cell Race at ASCB meeting
6. Worlds first captive breeding of Ozark hellbenders at Saint Louis Zoo
7. Genetic code of first arachnid cracked
8. Genetic study confirms: First dogs came from East Asia
9. First study to reveal how paracetamol works could lead to less harmful pain relief medicines
10. West coast log, lumber exports in first 9 months of 2011 surpass 2010 totals
11. Paleontologist describes large nest of juvenile dinosaurs, first of their genus ever found
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology: